Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If you can stop a pancreatic cancer directly with CR-T there may be no need for all of prev chemo, and for much of current anti cancer drug therapy
of course your question is the right one:
could K help CAR-T achieve better results?
The answer will be years away from understanding, as we have yet to see K even join forces with conventional chemo (the upcoming.....waiting...waiting for it.....trial)
would LOVE to hear some discussion of K/CAR-T alliance-
Too bad they have not given this short half life drug more than once a week....
Too bad they have shown no real benefits.....
U Penn researchers announce today ability to stop pancreatic CA in mice with a double target approach using CAR-T. In other words, they are getting closer to solid tumor targets now- whereas they were not so successful before.
C'mon CTIX let's get it in gear for Kevetrin, while there is still a chance that K can find a niche in anti-cancer regimens, perhaps even with CAR-T treatments
Possible that CAR-T will render K irrelevant- yes of course we all know there is that risk. It may have even been mentioned on the board that biotech investing is risky
Het it's right here in good old Boston-
Too bad there is nothing about 1807 and the attempt to manipulate the drug for Pseudomonas coverage
Can we look forward to another PR tomorrow from the CEO? Where we are told that he is still invigorated, and not hamstringed? Where we hear that there will be a piece of chocolate on every pillow, and the for 2 days(Sat and Sunday) the price will not decline?
Or maybe we will find out the B-UP trial country???
The suspense builds
My yeesh means only that- what they expected back is very different from how things have actually gone.
And no of course I would expect no company to meet all of its goals, since they are only that, goals
And yes my patients, and I, or my family members, when we are patients, understand the imperfect nature of forward looking statements, whether that pertains to an ED visit, or to corporate plans.
I prefer to look carefully life's failed ambitions, including my own.
I realize your zen approach to ctix- do not question the short run,it is an investment- does not allow for such musings. But I cannot avoid it, and so we will continue express our concerns differently.
Yeesh, another tough read
11/13 B potential discussed by ctix, many possible targets.
At same time company says aml bologna and renal cell ca with BI starting in 2014....
Right.
Very very helpful data, about rates of remission without treatment, to provide some sense of the lay of the land. For sure they would need good data to move forward, and one can only hope.
Let's say it does not work out- why are they so set on this after all? What data do they have that we do not know? I am in the midst of sitting down at the day's end to read every bit of info I can find about B and distal colitis, call it what you will. Will look back at PMX when I get the chance- soon, now
But even so, Leo said that he would move forward if data fr B-OM looked good. Not just no side effects but some postive indications. So B-OM must be showing some benefit, right? Is this too much to presume?
And they hire Sonis?
And they hire Farraye?
So even worst case B-UP is a flop it means B-OM must look ok, and there are still many possibilities for other B uses, sorry to be repetitive, conjunctivitis, blepharitis, HS.
Just starting to look back at all the B-UP stuff I get right into 3/30/6 B-UP to go ahead- country unnamed-and Jorgensen out. And then 1/26/15 B-UP look good, and by the way, ctix moving forward with plns to uplist on NASDAQ-sigh.....
One finds oneself right back in annoying waters, or mud, maybe more accurately, with just the very start of the search, to learn all there is to know about Brilacidin and ulcerative colitis(distal).
And yet I will read on undeterred, as many of you are no doubt also doing even now.
pretty funny frrol- I cannot help but think that- hurrah!-positive results in B-UP demo will MOVE the share price(although of course somewhat positive P results got us nothing')
So I cannot achieve the meditative state I need to reach-
Maybe in a next life
For now still tethered to share price for ctix....
country for B-UP? Still not disclosed?
Huh?
Gotta love the intrigue, but why?
Pretty exciting stuff!!!
B-UP now in play
Remember the mice with psoriasis graft photos? Well, get ready for some rectal photos, appearing soon on the CTIX site.
You can get your bottom dollar(sigh) on that!
At least there will be photos if it works.
I wish there were a comparison with steroid foam or enema(Cortenema) but obv proof of concept comes first.
Pls pls pls let this show some benefit!
Yep- do not focus on share price
watch the long event horizon
the company has an amazing set of products for an unknown stock selling for peanuts, or for a little more than a container of soy milk, or about the cost of a cucumber, or whatever
it is hard for me to get past the attn. to share price when it determines how many shares I can afford
But I am trying to achieve your recommended zen biotech vision
Certainly the disastrous drop in price has helped me tremendously I cannot focus on price too much since it is such a downer
But seriously, the products here are potentially amazing- so I will think about that
On that note- we are now more than 2 years behind apr-246. Will Kevetrin be that much better? That is the largest long term question mark for ctix for me
Bp3 only brief and minor impact share price- sad but true
Mayo pancreatic- surely you jest- we woulda heard by now. Waiting on 1B baby, for k ovarian Just 2 years to wait, that's all
peer review K- no new info, no impact even smidge
stock goes nowhere till partnership or B-OM news
even the start of B-UP means nothing to share price, though it means a great deal to us longs
Leo's weekend invigoration- means nothing
Over 2 by the end of 2016? Is there any chance?
Sure:
If partnership
If good interim data from B-OM(but enrollment not so brisk acc to Leo's comments in CA)
Otherwise, not a chance
Look forward to coherent arguments to contrary
Your sigh is well taken
I did not listen to audio- my fault
will check it out
Thank you-
Brilacidin for Hidradenitis Sup, as before not acne
But now that it is written,I wonder if it could work for acne- it might
Unsure if any activity for propioibacterium acnes but might work- look at all of the systemics and topicals that are used for acne
I think he was referring to HS but what the heck- it may well be beneficial for regular old acne
now that would be a market
Embarrassed to write this since i musta missed it- six weeks only for B-UP? Can you just say where you saw this? Thank you. If true v good news- so quick
Leo thanked us for unwavering support, when In fact plenty of shareholders have wavered the share price way way down....
A day at the track? day trading? look, I enjoy hyperbole as much as anyone, but...
This amount of hitting one's hand with a ruler for saying that there are no big share price drivers at the moment?
a bit punitive in tone. Which is what you intended obv.
We agree, actually, that this is a long term proposition. Who could expect otherwise? Seriously?
No momentum for any company or in investing? Gosh when Leo sent out his Friday thanks for the unwavering support missive, and spoke of the Prurisol phase 2 results plus the dismissal of the suit, I think he was sorta talking about the accumulation of good news, you know, momentum
Hamstringed makes me cringe but your explanation is both amusing and informative.
He should have just chosen another word.
OK I see You do care
And so do I.
But maybe I just care ... too much
And so as the days go by, as we head deeper into June, I am troubled
What a shame to fall into the imply - infer abyss
So we have a different set of expectations. I expect to hear more about a trial that was announced to start no less than 10 days ago. You on the hand do not care
I would prefer an update , or better yet, the trial start
the start of the Brilacidin for ulcerative proctitis trial was supposed to be during the month of May according to previous press releases. We are now 10 days into June…
I hesitate to mention this because the response of the board will be you to know that this is biotech and you do know that promises are not always kept, right?
however, it is the only thing now we have to rely on for any momentum, esp if update about B-HS and B-OM
sad truth is the suit dismissal has not made any significant share price
decent but not great results for prurisol made no difference
I still believe K 1b/2 ovarian start and B p3 starts will not help beyond a small bump for a day or two- if that even. Of course a partnership would change everything- don't hold your breath
So now we are left only with the antiinflammatory B uses for any hope of a bump
B-UP start update of B-HS and news from B-OM- only current hope for many months, possibly even a couple years-
brady pushes no huddle offense gotta like that thought
OK ctix so now please announce start of B-UP(like you said would start in May, remember,?) and maybe tell us about B-OM interim info
That might move the share price
pls see post 150617 for the answer
sorry - do not get the mr sullivan thing
and your counterargument is....
One last try: it is ASCO 2018 , and someone at the podium is detailing responses to the recently completed dose escalation 1B phase of the Kevetrin /Doxorubicin trial for ovarian cancer.
The data show excellent safety results
The data also show that 10% of patients had a 20% decrease in CA-125 and 15% had stable disease for 3 months.
As part of the 1B, when there was excellent safety but little response, the k dose was doubled and K was given 4x weekly, along with maximal Doxorubicin dose, but there was still no change in patient response.
Does the trial proceed? No. Was safety demonstrated- of course. Was efficacy one of the aims of the 1B part of the 1B/2 study? No, safety was the endpoint.
Nonetheless such data would not be good enough to proceed K p2 ovarian CA trial.
They can show safety but they will also have to demonstrate some efficacy. How much, I do not know. But it has to be
So we disagree.
Look- I hope the 1b will be super, and that Kp2 will be super, and that the rest of the phase 2's will be launched.
But 1B has to succeed or K will not be OK- see my recent response to KMBJN for more detail
OK. I get that safety needs to be shown if no prev trial of 1) K given 3x week, and 2) K plus chemo agent, and that 1b will be to demonstrate that safety.
You spell out the safety data for apr-246. Of course they need to prove safety, but suppose only 6 or 8 of their trial patients were deemed responders. Can we all agree that there would be no round of fundraising and no moving forward with rest of the trial? They have to show some response at planned levels of dosing. They cannot show just safety. They had to show strong data like 18 of 24 pts improving, otherwise it is hopeless.
In the same way K plus doxorubicin cannot just show safety - it must show some very good response rate . Otherwise, it will be game over, even though initial part of the trial is for safety, or to define dosing.
Can you explain how 1/3 of patients responding- by whatever criteria , CA-125 RECIST - for K/doxorubicin will lead to trial completion? APR-246 would have been halted with such data, and so will be K if that happens.
And yes, of course I am worried that all of the eggs are in the ovarian CA basket and failure with 1b will be the end of K. Leo just announced that no other phase 2's are moving forward and the focus is on ovarian CA. They have to succeed there, or who knows if K will get a chance with other tumors.
With respect to other doses, or more x per week, I would expect that to be part of expanded or planned 1B for ovarian trial - dose escalation
Of course it is meaningless
trying to answer your question of why no bounce with dismissal
SA article yesterday where author says dilution anticipated for trials and, in his opinion, shares are worth one dollar not 1.50
It does not matter one whit
If they are giving their carefully chosen chemo agent plus 3x weekly dosing K and there is no clear benefit, it is over
despite the fact that the first bit of the trial is for safety
Does anyone else on the board believe this?
That if Aprea had no benefit whatsoever in 1B that they would be moving forward?
they would not, not at all.
And CTIX cannot move forward with K at 1B endpoint without efficacy
What is up with this?
1b- Doxorubicin plus kevetrin, where K will be given 3x week(we think- or maybe at different doses or 2 x a week or 4 x a week), must demonstate efficacy or the trial will be over.
If you, and other board members, want to insist - for some semantic sentimental reasons- that the phase 2 part counts even just a little bit, ok by me, but in name only
1b determines stop or go
or even call it 1B/2-officially of course it is a 1B/2- it matters not a whit
1B is all that really counts anymore
1B
or not 1B
it has nothing to do with the mongering of fear
It has to do with the winnowing of possibilities and expectations
Not so long ago CTIX pr chatter was all about phase 2's for K
Now, not so much
The chatter is now 1b, or bust
Not to worry though- all of you guys knew it along, right, knew it was coming to this point, despite the previous talking up of all the other cancers and potential trials and partnerships- pancreatic and retinoblastoma and Mayo and MD Andersen and Bologna and AML
And yet here we are- 1b or bust
But you knew it already? Right?
K 1B ovarian CA
That is all there is for now. A new reality.
No p2 renal
No p2 pancreatic
No AML Bologna
all the hype and talk and promise boils down to this-
Big woop if 2 is part of 1b
who said otherwise- what I said is failure of 1B means NO P2
Are any of you seriously questioning that?
Let's see- Aprea presented at ASCO yesterday and they presented 1b results for PISSARO
1B
In preparation for phase 2
How could this possibly differ for CTIX and Kevetrin? Oh yeah - it won't
Sorry, out of posts for the day
You are kidding, right?
If apr-246 has no efficacy then the phase 2 part of the 1b/2 is cancelled And then there is no ASCO presentation yesterday by Aprea.
And if K 1B shows no efficacy the trial will be over.
Surely you are not suggesting they would move on with a Kevetrin trial that shows no promise in 1B? It must demonstrate efficacy in 1B
None of the recent PR's have mentioned a monotherapy arm for p2. Yes of course it was mentioned quite a while back- but No recent mention(last several p2 K pr's) That trial arm might have gone by the wayside-
and despite what you say 1B will precede 2 absolutely.
Once again, the example of apr-246 is a simple and gentle reminder that 1B might be the last we see of K(though I hope not)
1B will absolutely be a make or break